- 专利标题： METHODS OF TREATING MULTIPLE MYELOMA CANCERS EXPRESSING HIGH LEVELS OF EPO-RECEPTOR USING PSA-EPO
-
申请号： US16608781申请日： 2018-04-25
-
公开(公告)号： US20200179524A1公开(公告)日： 2020-06-11
- 发明人: Dmitry Genkin
- 申请人： Lipoxen Technologies Limited
- 申请人地址： GB London
- 专利权人： Lipoxen Technologies Limited
- 当前专利权人： Lipoxen Technologies Limited
- 当前专利权人地址： GB London
- 国际申请： PCT/EP2018/060562 WO 20180425
- 主分类号： A61K47/60
- IPC分类号： A61K47/60 ; A61K38/18 ; A61K47/61 ; A61P35/00
摘要：
The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid.